Wall Street brokerages expect VIVUS, Inc. (NASDAQ:VVUS) to post earnings of ($1.10) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.60) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 83.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that VIVUS will report full year earnings of ($4.40) per share for the current year. For the next year, analysts expect that the business will report earnings of ($5.70) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for VIVUS.
VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.08). The business had revenue of $14.96 million for the quarter.
VVUS has been the topic of several research analyst reports. Zacks Investment Research cut shares of VIVUS from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. ValuEngine raised shares of VIVUS from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 12th.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC boosted its holdings in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the period. Renaissance Technologies LLC owned approximately 7.79% of VIVUS worth $5,833,000 as of its most recent SEC filing.
VIVUS stock traded up $0.19 during trading hours on Friday, hitting $4.74. 59,621 shares of the stock were exchanged, compared to its average volume of 90,262. The company has a current ratio of 4.93, a quick ratio of 4.26 and a debt-to-equity ratio of -10.60. The stock has a market capitalization of $46.98 million, a price-to-earnings ratio of -1.63 and a beta of 0.58. VIVUS has a 12 month low of $3.30 and a 12 month high of $9.90.
VIVUS Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Recommended Story: Insider Trading – What You Need to Know
Get a free copy of the Zacks research report on VIVUS (VVUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.